Inferring alterations in cell-to-cell communication in HER2+ breast cancer using secretome profiling of three cell models

Biotechnology and Bioengineering

Volumn 111, Issue 9, 2014, Pages 1853-1863

  Klinke, David J ^a,b   Kulkarni, Yogesh M ^a,c   Wu, Yueting ^a   Byrne Hoffman, Christina ^b  

^a West Virginia University   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c HAMPTON UNIVERSITY   (United States)

Author keywords

Exosomes; Intercellular communication; Proteomics; Selective fitness landscape; Somatic evolution; Tumor immunology

Indexed keywords

CELL CULTURE; CELL SIGNALING; CELLS; DISEASES; ELECTROPHORESIS; MASS SPECTROMETRY; MOLECULAR BIOLOGY; RANDOM PROCESSES; SCANNING ELECTRON MICROSCOPY; TUMORS;

EXOSOMES; FITNESS LANDSCAPE; INTERCELLULAR COMMUNICATIONS; PROTEOMICS; SOMATIC EVOLUTION; TUMOR IMMUNOLOGIES;

PROTEINS;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EZRIN; PROTEIN; PROTEOME;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL COMMUNICATION; CELL ENERGY; CELL MEMBRANE; CONTROLLED STUDY; EXOSOME; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SCANNING ELECTRON MICROSCOPY; SECRETOME; TWO DIMENSIONAL GEL ELECTROPHORESIS; EPITHELIUM CELL; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS); TUMOR CELL LINE; ULTRASTRUCTURE;

CELL COMMUNICATION; CELL LINE, TUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EPITHELIAL CELLS; EXOSOMES; HUMANS; MICROSCOPY, ELECTRON, SCANNING; PROTEINS; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84905004665     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25238     Document Type: Article

References (63)

1. Bobrie A, Krumeich S, Reyal F, Recchi C, Moita LF, Seabra MC, Ostrowski M, Thery C. 2012. Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res. 72(19):4920-4930.
2. Chang CH, Curtis JD, Maggi LB, Faubert B, Villarino AV, O'Sullivan D, Huang SC, van der Windt GJ, Blagih J, Qiu J, Weber JD, Pearce EJ, Jones RG, Pearce EL. 2013. Post-transcriptional control of T cell effector function by aerobic glycolysis. Cell 153(6):1239-1251.
3. Csete ME, Doyle JC. 2002. Reverse engineering of biological complexity. Science 295(5560):1664-1669.
4. Goentoro LA, Reeves GT, Kowal CP, Martinelli L, Schupbach T, Shvartsman SY. 2006. Quantifying the Gurken morphogen gradient in Drosophila oogenesis. Dev Cell 11(2):263-272.
5. Greaves M, Maley CC. 2012. Clonal evolution in cancer. Nature 481(7381):306-313.
6. Haller MF, Saltzman WM. 1998. Localized delivery of proteins in the brain: Can transport be customized? Pharm Res 15(3):377-385.
7. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144(5):646-674.
8. Henningsen J, Rigbolt KT, Blagoev B, Pedersen BK, Kratchmarova I. 2010. Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol Cell Proteomics 9(11):2482-2496.
9. Herrmann F, Lehr HA, Drexler I, Sutter G, Hengstler J, Wollscheid U, Seliger B. 2004. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 64(1):215-220.
10. Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253(5015):49-53.
11. Hsu PP, Sabatini DM. 2008. Cancer cell metabolism: Warburg and beyond. Cell 134:703-707.
12. Huang DW, Sherman BT, Lempicki RA. 2009a. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37(1):1-13.
13. Huang DW, Sherman BT, Lempicki RA. 2009b. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57.
14. Kicheva A, Pantazis P, Bollenbach T, Kalaidzidis Y, Bittig T, Julicher F, Gonzalez-Gaitan M. 2007. Kinetics of morphogen gradient formation. Science 315(5811):521-525.
15. Klinke DJ. 2010. Signal transduction networks in cancer: Quantitative parameters influence network topology. Cancer Res 70(5):1773-1782.
16. Klinke DJ. 2013. An evolutionary perspective on anti-tumor immunity. Front Oncol 2:202.
17. Kulasingam V, Diamandis EP. 2007. Proteomics analysis of conditioned media from three breast cancer cell lines: A mine for biomarkers and therapeutic targets. Mol Cell Proteomics 6(11):1997-2011.
18. Kulkarni YM, Chambers E, McGray AJ, Ware JS, Bramson JL, Klinke DJ. 2012. A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model. Integr Biol (Camb) 4(8):925-936.
19. Kulkarni YM, Klinke DJ. 2012. Protein-based identification of quantitative trait loci associated with malignant transformation in two HER2+ cellular models of breast cancer. Proteome Sci 10(1):11.
20. Kulkarni YM, Suarez V, Klinke DJ. 2010. Inferring predominant pathways in cellular models of breast cancer using limited sample proteomic profiling. BMC Cancer 10:291.
21. Lasfargues EY, Coutinho WG, Redfield ES. 1978. Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst 61(4):967-978.
22. Logozzi M, De Milito A, Lugini L, Borghi M, Calabro L, Spada M, Perdicchio M, Marino M.L, Federici C, Iessi E, Brambilla D, Venturi G, Lozupone F, Santinami M, Huber V, Maio M, Rivoltini L, Fais S. 2009. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS ONE 4(4):e5219.
23. Makawita S, Smith C, Batruch I, Zheng Y, Ruckert F, Grutzmann R, Pilarsky C, Gallinger S, Diamandis EP. 2011. Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics 10(10):M111.008599.
24. Maruyama T, Mimura K, Sato E, Watanabe M, Mizukami Y, Kawaguchi Y, Ando T, Kinouchi H, Fujii H, Kono K. 2010. Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma. Br J Cancer 103(4):552-559.
25. Masuda ES, Luo Y, Young C, Shen M, Rossi AB, Huang BC, Yu S, Bennett MK, Payan DG, Scheller RH. 2000. Rab37 is a novel mast cell specific GTPase localized to secretory granules. FEBS Lett 470(1):61-64.
26. Mathivanan S, Fahner CJ, Reid GE, Simpson RJ. 2012. ExoCarta 2012: Database of exosomal proteins, RNA and lipids. Nucleic Acids Res 40(Database issue):D1241-D1244.
27. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. 2012. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482(7385), 400-404.
28. Merlo LM, Pepper JW, Reid BJ, Maley CC. 2006. Cancer as an evolutionary and ecological process. Nat Rev Cancer 6(12):924-935.
29. Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q. 2008. GeneMANIA: A real-time multiple association network integration algorithm for predicting gene function. Genome Biol 9(Suppl 1):S4.
30. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M. 2002. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1(5):376-386.
31. Ong SE, Kratchmarova I, Mann M. 2003. Properties of 13C-substituted arginine in stable isotope labeling by amino acids in cell culture (SILAC). J Proteome Res 2(2):173-181.
32. Pavlou MP, Dimitromanolakis A, Diamandis EP. 2013. Coupling proteomics and transcriptomics in the quest of subtype-specific proteins in breast cancer. Proteomics 13(7):1083-1095.
33. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, Lyden D. 2012. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18(6):883-891.
34. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman D, Varela I, Lin ML, Ordonez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, Beare D, Butler A, Carter RJ, Chen L, Cox AJ, Edkins S, Kokko-Gonzales PI, Gormley NA, Grocock RJ, Haudenschild CD, Hims MM, James T, Jia M, Kingsbury Z, Leroy C, Marshall J, Menzies A, Mudie LJ, Ning Z, Royce T, Schulz-Trieglaff OB, Spiridou A, Stebbings LA, Szajkowski L, Teague J, Williamson D, Chin L, Ross MT, Campbell PJ, Bentley DR, Futreal PA, Stratton MR. 2010. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463(7278):191-196.
35. Raposo G, Stoorvogel W. 2013. Extracellular vesicles: Exosomes, microvesicles, and friends. J Cell Biol 200(4):373-383.
36. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, Ratajczak MZ. 2006. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: Evidence for horizontal transfer of mRNA and protein delivery. Leukemia 20(5):847-856.
37. Reisinger V, Eichacker LA. 2008. Solubilization of membrane protein complexes for blue native PAGE. J Proteomics 71:277-283.
38. Schulze WX, Mann M. 2004. A novel proteomic screen for peptide-protein interactions. J Biol Chem 279(11):10756-10764.
39. Sepiashvili L, Hui A, Ignatchenko V, Shi W, Su S, Xu W, Huang SH, O'Sullivan B, Waldron J, Irish JC, Perez-Ordonez B, Liu FF, Kislinger T. 2012. Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy. Mol Cell Proteomics 11(11):1404-1415.
40. Shvartsman SY. 2005. Quantitative analysis of developing tissues. AIChE J 51(5):1312-1318.
41. Simpson RJ, Mathivanan S. 2012. Extracellular microvesicles: The need for internationally recognized nomenclature and stringent purification criteria. J Proteomics Bioinform 5:2.
42. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.
43. Sokolova V, Ludwig AK, Hornung S, Rotan O, Horn PA, Epple M, Giebel B. 2011. Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy. Colloids Surf B Biointerfaces 87(1):146-150.
44. Srirajaskanthan R, Caplin ME, Waugh MG, Watkins J, Meyer T, Hsuan JJ, Beaumont NJ. 2010. Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes. Mol Cell Proteomics 9(4):656-666.
45. Stenmark H. 2009. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol 10(8):513-525.
46. Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, Roychoudhuri R, Palmer C, Muranski P, Karoly ED, Mohney RP, Klebanoff CA, Lal A, Finkel T, Restifo NP, Gattinoni L. 2013. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest 123(10):4479-4488.
47. Taylor DD, Gercel-Taylor C. 2008. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110(1):13-21.
48. Thery C. 2011. Exosomes: Secreted vesicles and intercellular communications. F1000 Biol Rep 3:15.
49. Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S. 2001. Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 166(12):7309-7318.
50. Thiele EW. 1939. Relation between catalytic activity and size of particle. Ind Eng Chem 31(7):916-920.
51. Thurber GM, Zajic SC, Wittrup KD. 2007. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 48(6):995-999.
52. Trempe GL. 1976. Human breast cancer in culture. Recent Results Cancer Res 57:33-41.
53. Ullrich O, Stenmark H, Alexandrov K, Huber LA, Kaibuchi K, Sasaki T, Takai Y, Zerial M. 1993. Rab GDP dissociation inhibitor as a general regulator for the membrane association of rab proteins. J Biol Chem 268(24):18143-18150.
54. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9(6):654-659.
55. van der Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324:1029-1033.
56. van der Pol E, Boing AN, Harrison P, Sturk A, Nieuwland R. 2012. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev 64(3):676-705.
57. Warburg O. 1956. On the origins of cancer cells. Science 123(3191):309-314.
58. Wolski WE, Lalowski M, Jungblut P, Reinert K. 2005. Calibration of mass spectrometric peptide mass fingerprint data without specific external or internal calibrants. BMC Bioinformatics 6:203.
59. Wu CC, Hsu CW, Chen CD, Yu CJ, Chang KP, Tai DI, Liu HP, Su WH, Chang YS, Yu JS. 2010. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol Cell Proteomics 9(6):1100-1117.
60. Xue H, Lu B, Lai M. 2008. The cancer secretome: A reservoir of biomarkers. J Transl Med 6:52.
61. Yakoub D, Keun HC, Goldin R, Hanna GB. 2010. Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients. Cancer Res 70(22):9129-9136.
62. Yu X, Harris SL, Levine AJ. 2006. The regulation of exosome secretion: A novel function of the p53 protein. Cancer Res 66(9):4795-4801.
63. Zhang HG, Zhuang X, Sun D, Liu Y, Xiang X, Grizzle WE. 2012. Exosomes and immune surveillance of neoplastic lesions: A review. Biotech Histochem 87(3):161-168.